Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Intell Nanovax Biotech Co. Ltd. possesses a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this portfolio. The prosecution is being conducted by a lone distinct examiner within a lone distinct art unit. This indicates a focused and singular point of contact within the patent office for the company's current biotechnology filings. Such a narrow focus often points to a specific core technology being protected.
The busiest examiner, MORGAN, BAILEY MICHELLE, is responsible for 1 busiest examiner pending office action. This matches the total of 1 pending office action for the entire portfolio. Consequently, the company's immediate patent prospects in the Biotechnology & Pharmaceuticals field are entirely in the hands of this examiner. Practitioners should note that the lack of multiple distinct examiners or art units means there is no current diversification of examiner perspectives, making the relationship with this examiner paramount.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999335 | TUMOR VACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF | MORGAN, BAILEY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999335 | TUMOR VACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF | MORGAN, BAILEY MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17999335 | TUMOR VACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF | MORGAN, BAILEY MICHELLE | 1645 | §102§103§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntell Nanovax Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bailey Michelle Morgan has the most, with 1 of Intell Nanovax Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
